Document:

Exhibit 10.1

 

Employment Agreement

 

This Employment Agreement by and between Opiant Pharmaceuticals,
Inc. (the “Company”) and Phil Skolnick (the “Employee”) (collectively, the “Parties”) is entered
into by and between the Company and Employee effective as of February 6, 2017 (the “Effective Date”) (the “Agreement”).

 

WHEREAS the Company has requested that Employee provide services
beneficial to the Company;

 

WHEREAS the Company seeks to employ Employee as Chief Scientific
Officer;

 

NOW THEREFORE, in consideration of the mutual covenants herein
contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby mutually agree as follows:

 

		1)	Employee shall have such responsibility and authority as is customarily possessed and exercisable by the Chief Scientific Officer
of a corporation and Employee shall also perform such other executive and administrative duties consistent with the position of
Chief Scientific Officer as Employee may reasonably be expected to be capable of performing on behalf of the Company and any subsidiaries
and affiliates of the Company as may from time to time be authorized or directed by the Board of Directors of the Company (the
“Board”) (collectively, “the Services”). Employee shall report to the Chief Executive Officer of the Company
(the “CEO”).

 

		2)	Employee shall provide the Services from the Effective Date through August 5, 2017 (the “Term”), subject to the
other terms of this Agreement. Unless otherwise agreed in writing by Employee and the Company after August 5, 2017 this Agreement
shall remain in effect on a month-to-month basis (the “Extended Term”) unless either Employee or the Company provides
the other party with at least ten (10) business days written or electronic notice of termination of this Agreement, which termination
can be given for any legal reason. In the event of such termination, the termination provisions set forth in Section 7 of this
Agreement shall not be applicable and the Extended Term shall end at the end of month that is ten (10) business days after such
notice is sent.

 

		3)	During the Term, or the Extended Term to the extent it is applicable, Employee shall receive from the Company, on a pro rata
basis, annual base cash pay at a rate of US$410,000 per annum (the “Base Cash Compensation”), unless otherwise agreed
in writing by the Parties. Such Base Cash Compensation shall be paid by the Company to Employee in cash installments no less often
than monthly and shall be subject to all applicable payroll tax withholdings and deductions. In addition, Company shall pay Employee
a signing bonus of US$40,000 (the “Signing Bonus”) within fifteen (15) business days of Effective Date, which bonus
shall be subject to all applicable payroll tax withholdings and deductions.

 

     

     

    

 

Employee shall be eligible to earn an incentive bonus
in an amount and structure agreed upon by Employee and the Board and/or CEO. The amount of the incentive bonus payment shall be
determined based on the achievement of specific milestones, representing a combination of both individual management objectives
and corporate objectives. The Board and/or CEO shall, in its sole discretion, determine whether such objectives have been achieved,
and the amount of Employee’s incentive bonus, if any. Any bonus awarded hereunder shall be subject to applicable payroll
tax withholdings and deductions.

 

As a Company Employee, Employee shall accrue time
off (“PTO”) under the Company’s paid time off program.

 

For purposes of this Agreement, “Owed Amounts”
is defined as the total cash amounts owed by the Company to Employee, including, but not limited to, earned and unpaid Base Cash
Compensation, earned and unpaid bonus cash compensation, earned and unpaid PTO, and any other amounts owed by the Company to Employee,
including, but not limited to, amounts due to be reimbursed to Employee.

 

		4)	Employee shall be entitled to timely reimbursement of all reasonable expenses incurred by Employee in the performance of duties
in accordance with the Company’s policies.

 

		5)	Employee shall be granted options to purchase two hundred thousand (200,000) shares of the Company’s common stock (the
“Options”), each of which shall expire on the day that is the earlier of: (a) ninety (90) calendar days after Employee
ceases to provide Services pursuant to this Agreement, (b) ninety (90) calendar days after the Extended Term, to the extent it
is applicable, ends, (c) ninety (90) calendar days after the Term ends if there is no Extended Term, (d) Employee becomes subject
to a termination or fundamental transaction pursuant to Paragraph 7 of this Agreement, or (e) ten (10) years from the date of issuance
of such Options. Each Option shall be exercisable on a cashless basis at an exercise price equal to the higher of (a) $8.00, or
(b) the next higher round number above the Company’s closing stock price on the Effective Date (the higher of (a) or (b)
being the “Exercise Price”). By way of example, if the closing price of the Company’s stock on the Effective
Date is $12.75, the Exercise Price of each Option shall be $13.00. By way of example, if the closing price of the Company’s
stock on the Effective Date is $7.75, the Exercise Price of each Option shall be $8.00. One hundred thousand (100,000) of the Options
shall vest on the eighteenth month anniversary of the issue date of the Options. Five thousand five hundred fifty-five (5,555)
of the Options shall vest on each of the nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth
and twenty-sixth anniversaries of the Effective Date. Five thousand five hundred fifty-six (5,556) of the Options shall vest on
each of the twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, thirty-fifth
and thirty-sixth anniversaries of the Effective Date. Such Options shall have other terms as determined by the Board.

 

     

     

    

 

Such Options shall be exercisable in the form of Notice
of Stock Option Grant attached as Exhibit A hereto, which Options may be exercised, where applicable, pursuant to the form of Notice
of Exercise of Stock Option (the “Exercise Notice”) attached as Exhibit B hereto.

 

Upon the exercise of such Options, the fair market
value per share of common stock of the Company (the “Common Stock”) (with each share of Common Stock, a “Share”)
shall be equal to the closing price of the Shares of Common Stock of the Company on the day prior to such exercise. Exercise of
these Options shall occur by Employee’s: (i) surrendering the exercised Options at the principal office of the Company together
with a properly completed and signed Notice of Exercise of Stock Option (as per Exhibit B hereto), and (ii) providing via email
a readable .pdf or scan of all of the documentation set forth in (i) to the email addresses of the Chief Executive Officer, Chief
Financial Officer and Controller (if the Company has a Controller at such time) of the Company at the time of such surrender (the
current applicable email addresses being: rcrystal@opiant.com and kpollack@opiant.com).

 

Upon exercise of these Options pursuant to the terms
of the prior paragraph, the number of Shares of Common Stock to be issued to Employee shall be computed using the following formula:

 

	X =	Y(A-B)	 
	 	A	 

 

	Where X =	the number of Shares of Common Stock to be issued to Employee
	 	 
	Y =	the number of Shares of Common Stock purchasable under the Options or, if only a portion of the Options are being exercised, the portion of the Options being exercised (at the date of such calculation)
	 	 
	A =	the closing price of one Share of the Common Stock on the day prior to such exercise (as adjusted to the date of such calculation)

 

     

     

    

 

	B =	the Exercise Price per Share (as adjusted to the date of such calculation)

 

In the event of Employee’s death, any vested
Options, vested options or vested warrants held shall be transferrable to Employee’s estate (or as may otherwise be provided
for by Employee. In the event of Employee’s death, any Options, options or warrants held that have not vested shall not be
transferrable to Employee’s estate (or as may otherwise be provided for by Employee. No amendment, modification or termination
of any equity grant document or any stock option awards and warrant awards shall, without the consent of Employee, materially impair
any rights or obligations under any grant made to Employee.

 

		6)	Employee shall be eligible to participate in the Company’s employee benefit plans (including
medical, dental, vision and 401(k) plans), subject to eligibility requirements and the requirements of such plans. Details about
these benefit plans shall be made available at Employee’s request. The Company reserves the right to modify or terminate
benefits from time to time as it deems necessary or appropriate.

 

		7)	The termination provisions and fundamental transaction provisions applicable to Employee are as follows:

 

		a.	Termination of Employment by the Company for Cause: Notwithstanding anything herein to the contrary, during the Term or Extended
Term, to the extent it is applicable, the Company may terminate this Agreement at any time for Cause (as hereinafter defined).
In such an event Employee shall be deemed effectively terminated as of the time of delivery of such notice. For the avoidance of
doubt, there will be no severance pay or other special payment upon such termination of employment by the Company for Cause and
the Company shall not be obligated to provide any further compensation to Employee, except that Employee shall be entitled to all
such options and warrants that have vested, and all Owed Amounts to which Employee is entitled to through the date of such termination
and the Company shall pay Employee (or Employee’s estate, as soon as practicable after Employee’s death, if earlier)
all such Owed Amounts within sixty (60) days after the date of such termination. For purposes of this Agreement, “Cause”
means: termination based upon Employee’s (i) willful breach or willful neglect of his duties and responsibilities; (ii) conviction
of or a plea of no contest with respect to a felony occurring on or after the execution of this Agreement; (iii) material breach
of this Agreement; (iv) acts of fraud, dishonesty, misappropriation, or embezzlement; (v) willful failure to comply with the Board’s
reasonable orders or directives consistent with Employee’s position; or (vi) becoming disqualified or prohibited by law from
serving as Chief Scientific Officer of the Company; provided, however, that in the case of any act or failure to act described
in clauses (i), (iii), or (v) above, such act or failure to act will not constitute Cause if, within ten (10) days after notice
of such act or failure to act is given to Employee by the Company, Employee has corrected such act or failure to act (if it is
capable of correction).

 

     

     

    

 

		b.	Termination of Employment by the Company without Cause and Severance Benefits Awarded: If during the Term or extended Term,
to the extent it is applicable, the Company terminates Employee’s employment or if Employee resigns within twelve (12) months
of a Constructive Termination (as hereinafter defined) of Employee’s employment, and in either case such termination is not
for Cause, then the Company shall pay Employee (or Employee’s estate, as soon as practicable after Employee’s death,
if earlier) within sixty (60) days after the date of such termination the sum of: (i) all Owed Amounts to which Employee is entitled
to; (ii) (1) times the Base Cash Compensation; and (iii) one (1) times the bonus cash compensation, excluding the Signing Bonus,
awarded to Employee, regardless whether paid to Employee, during 2017. In the event of such termination, all outstanding stock
options, warrants, restricted share awards, performance grants and the like held by Employee on Employee’s last day of service
shall become fully vested and remain exercisable for the life of such award and shall not be forfeited for any reason whatsoever.
Constructive Termination shall occur if, unless otherwise agreed in writing or electronically between Employee and the Company:
(i) either (A) there is a reduction of any amounts of Employee’s compensation set forth in this Agreement or a reduction
in annual cash pay or a material adverse change to the incentive plan that affects Employee differentially and adversely from other
employees, management, and/or officers with comparable levels of responsibility; (B) there is a material change in Employee’s
authority, duties, or responsibilities, including without limitation Employee’s ceasing to be the Chief Scientific Officer,
or Employee’s no longer being part of the executive team; (C) upon the Company’s or its successor’s reasonable
request, Employee refuses to relocate to a facility or location more than twenty (20) miles from Employee’s location at such
time; (D) Employee is subjected to discrimination, harassment or abuse as a result of Employee’s race, color, religion, creed,
sex, age, national origin, sexual orientation, or disability; (E) there is a failure of a successor of the Company to assume the
obligations of this Agreement; or (F) there is a material breach by the Company of this Agreement; and (ii) Employee provides the
Board written notice within thirty (30) days after the occurrence of one or more of the above events in (i); and (iii) the Board
does not remedy the condition so identified within thirty (30) days.

 

     

     

    

 

		c.	Termination of Employment Due to Disability and Severance Benefits Awarded: The Company may terminate Employee’s employment
for disability. In the event of a termination as a result of Employee’s disability, the Company shall pay Employee (or Employee’s
estate, as soon as practicable after Employee’s death, if earlier) on the date which is sixty (60) days after the date of
such termination the sum of: (i) all Owed Amounts to which Employee is entitled to; (ii) (A) one (1) times the Base Cash Compensation;
and (iii) one-half (0.5) times the bonus cash compensation, excluding the Signing Bonus, awarded to Employee, regardless whether
paid to Employee, during 2017. In the event of such termination, all outstanding stock options, warrants, restricted share awards,
performance grants and the like held by Employee on Employee’s last day of service shall become fully vested and remain exercisable
for the life of such award and shall not be forfeited for any reason whatsoever.

 

		d.	Benefits Following a Fundamental Transaction: To the extent that during the Term there shall be a Fundamental Transaction (as
hereinafter defined), notwithstanding any term to the contrary in this Agreement, Employee shall be entitled to receive the Fundamental
Transaction Compensation (as hereafter defined). For purposes of this Agreement, a “Fundamental Transaction" shall means
the Company, directly or indirectly, in one or more related transactions effects, complete or consummates, as applicable any (i)
merger or consolidation of the Company with or into another person, or (ii) reclassification, reorganization or recapitalization
of the Company’s common stock or any compulsory share exchange pursuant to which the Company’s common stock is effectively
converted into or exchanged for other securities, cash or property, (iii) sale, lease, license, assignment, transfer, conveyance
or other disposition of 50% or more of its assets, (iv) purchase offer, tender offer or exchange offer (whether by the Company
or another person) pursuant to which holders of Company’s common stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Company’s common
stock, or (v) stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another person or group of persons whereby such other person or group
acquires more than 50% of the outstanding shares of Company’s common stock (not including any shares of Company’s common
stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making or
party to, such stock or share purchase agreement or other business combination). For all purposes of this Agreement, the term Fundamental
Transaction Compensation shall mean the sum of: (i) all Owed Amounts to which Employee is entitled to; (ii) one (1) times the Base
Cash Compensation; and (iii) one (1) times the bonus cash compensation, excluding the Signing Bonus, awarded to Employee, regardless
whether paid to Employee, during 2017. In the event of a Fundamental Transaction, all outstanding stock options, warrants, restricted
share awards, performance grants and the like held by Employee on Employee’s last day of service shall become fully vested
and remain exercisable for the life of such award and shall not be forfeited for any reason whatsoever. Unless the Board shall
reasonably determine otherwise in good faith, in the event that the Company effects a Fundamental Transaction, each option and
warrant then outstanding (the “Equity Grants”) shall be fully exercisable regardless of the exercise schedule otherwise
applicable to such Equity Grant. The holder of such Equity Grant, and the shares underlying such Equity Grant, shall have the right
to receive the consideration per share receivable by other holders of shares of the Company’s common stock as a result of
such Fundamental Transaction. If holders of shares of the Company’s common stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction with respect to the shares, then the Equity Grant holder shall be
given the same choice. Notwithstanding the foregoing, in the event of a Fundamental Transaction and if the Board may reasonably
determine in good faith, the Equity Grants may be (i) honored or assumed, or new rights substituted therefore (such honored, assumed
or substituted award hereinafter called an “Alternative Award”), by the Company or its affiliates or any successor
entity in the Fundamental Transaction immediately following the Fundamental Transaction; provided that any such Alternative
Award must provide each holder with (a) rights and entitlements substantially equivalent to or better than the rights, terms and
conditions applicable under the Equity Grant and (b) substantially equivalent value to such Equity Grant (determined at the time
of the Fundamental Transaction); or (ii) purchased by the Company by paying to the holder an amount of cash equal to the value
of the remaining unexercised portion of the Equity Grant on the date of the consummation of such Fundamental Transaction to be
determined by a reasonable method selected by the Board in good faith. In the event that a successor entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of Equity Grants referring
to the “Company” shall refer instead to the successor entity) the Company, such successor entity may exercise every
right and power of the Company and shall assume all of the obligations of the Company under Equity Grant with the same effect as
if such successor entity had been named as the Company therein. The Fundamental Transaction Compensation shall be paid to Employee
within twenty (20) days of the Fundamental Transaction. For avoidance of confusion, in the event of a Fundamental Transaction while
Employee is employed by the Company, Employee shall be entitled to the Fundamental Transaction Compensation and not any other termination
compensation set forth elsewhere in this Paragraph 7. In the event that Employee is terminated for any reason and within one (1)
year of termination there is a Fundamental Transaction, then Employee shall be entitled to the Fundamental Transaction Compensation.

 

     

     

    

 

		8)	Except as otherwise provided herein, in the event that: (a) there is no termination of Employee or a Fundamental Transaction
as per the terms of Paragraph 7 herein; and (b) Employee either (i) fails to provide the Services during the Term, or the Extended
Term to the extent it is applicable; or (ii) leaves the employ of the Company before the end of the Term, or the Extended Term
to the extent it is applicable, then Employee shall waive: (a) all rights to any Base Cash Compensation not yet earned; (c) all
rights to any bonus compensation not yet earned; (d) all rights to any PTO not yet earned; (e) all rights to any options not yet
issued and to any options not yet vested; and (f) all rights to the benefit plans set forth in Paragraph 6 herein, except that
Employee shall receive four (4) months of such benefit plans, to the extent Employee already has such benefit plans in place, and/or
relevant reimbursements. Notwithstanding the foregoing, Employee shall be entitled to keep all vested warrants and options that
have been issued to Employee and Employee shall be entitled to all Owed Amounts to which Employee is entitled to, which Owed Amounts
shall be paid by the Company to Employee within sixty (60) days.

 

		9)	Covenants by Employee

 

		(a)	Property of the Company.

 

(1)     Employee
covenants and agrees that upon the termination of this Agreement for any reason or, if earlier, upon the Company’s request,
Employee shall promptly return all Property which had been entrusted or made available to Employee by the Company.

 

(2)     The term
“Property” shall mean all records, files, memoranda, drawing, plans, sketches, tests and experiments, results, reports,
keys, codes, computer hardware and software, price lists and other property of any kind or description prepared, used or possessed
by Employee during the engagement (and any duplicates of any such property) together with any and all information, ideas, concepts,
discoveries, and inventions and the like conceived, made, developed or acquired at any time by Employee individually or with others
during the engagement which relate to the Company’s business, products or services.

 

     

     

    

 

		(b)	Intellectual Property - Definitions.

 

(1)     “Intellectual
Property Rights” means all rights in and to U.S. and foreign (i) patents, patent disclosures and inventions (whether patentable
or not), (ii) trademarks, service marks, trade dress, trade names, logos, corporate names and domain names, and other similar designations
of source or origin, together with the goodwill symbolized by any of the foregoing, (iii) copyrights and copyrightable works (including
computer programs), and rights in data and databases, (iv) trade secrets, know-how and other confidential information, and (v)
all other intellectual property rights, in each case whether registered or unregistered and including all registrations and applications
for, and renewals or extensions of, such rights, and all similar or equivalent rights or forms of protection in any part of the
world.

 

(2)     “Pre-existing
Intellectual Property Rights” means all Intellectual Property Rights owned by Employee or by Employee jointly with any third
parties, which were created or invented by Employee prior to the period of this Agreement by and relate in any way to the business
or contemplated business, activities, research or development of the Company, including but not limited to any invention and works
of authorship and any registrations and applications arising from or related to the foregoing.

 

(3)     “Work
Product” means all writings, works of authorship, technology, inventions, discoveries, processes, techniques, methods, ideas,
concepts, research, proposals, materials and all other work product of any nature whatsoever, that are created, prepared, produced,
authored, edited, amended, conceived or reduced to practice by Employee individually or jointly with others during the period of
this Agreement (including prior to the Effective Date) and relating in any way to the business or contemplated business, products,
activities, research or development of the Company or resulting from any work performed by Employee for the Company (including
prior to the Effective Date and, in each case, regardless of when or where the work product is prepared or whose equipment or other
resources is used in preparing the same), all rights and claims related to the foregoing, and all printed, physical and electronic
copies and other tangible embodiments thereof.

 

     

     

    

 

		(c)	Pre-existing Intellectual Property Rights. Employee
hereby acknowledges and agrees that:

 

(1)     Employee
has attached as Exhibit C to this Agreement a list describing with particularity any Pre-existing Intellectual Property Rights,
including, if applicable, titles and registration and application numbers. The Pre-existing Intellectual Property Rights
listed in Exhibit C will be owned by or assigned to the Company under this Agreement. Any Pre-existing Intellectual
Property Rights not specifically listed in Exhibit C will be retained by Employee and will not be owned by or assigned to
the Company under this Agreement.

 

(2)     To
the extent that Employee incorporates any Pre-existing Intellectual Property Rights into any Work Product during
the period of this Agreement, Employee hereby irrevocably grants to the Company a royalty-free, fully paid-up, perpetual, transferable,
worldwide non-exclusive license (with the right to sublicense) to make, have made, copy, modify, make derivative works
of, use, offer to sell, sell, import and otherwise distribute such Pre-existing Intellectual Property Rights as
part of or in connection with such Work Product, and to practice any method related thereto.

 

		(d)	Work Product. Employee hereby acknowledges and agrees
that:

 

(1) All right,
title and interest in and to all Work Product as well as any and all Intellectual Property Rights therein and all
improvements thereof shall be the sole and exclusive property of the Company.

 

(2) The Company
shall have the unrestricted right, in its sole and absolute discretion, whether or not to (A) use, commercialize or market
any Work Product or (B) file an application for patent, copyright registration or any other Intellectual Property Rights and
prosecute or abandon such application prior to issuance or registration. No royalty or other consideration shall be due or owing
to Employee now or in the future as a result of such activities.

 

(3) The Work Product
is and shall at all times remain the confidential information of the Company.

 

     

     

    

 

(e)           Work
Made for Hire; Assignment. Employee acknowledges that, by
reason of being engaged as a Employee by the Company at the relevant times, to the extent permitted
by law, all Work Product consisting of copyrightable subject matter is “work made for hire” as defined in the Copyright
Act of 1976 (17 U.S.C. § 101), and such copyrights are therefore owned by the Company.
To the extent that the foregoing does not apply, Employee hereby irrevocably assigns to the Company, and its successors and assigns,
for no additional consideration, Employee’s entire right, title and interest in and to all Work Product, including the right to
sue, counterclaim and recover for all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding
thereto throughout the world. Nothing contained in this Agreement shall be construed to reduce or limit the Company’s rights,
title or interest in any Work Product or Intellectual Property Rights so as to be less in any respect than
the Company would have had in the absence of this Agreement.

 

(f)           Disclosure
of Work Product; Maintenance of Records. During this Agreement, Employee
shall promptly make written disclosures to the Company of all
Work Product, and shall at all times keep and maintain adequate, current, accurate, and authentic records of all Work Product.
Such records may be in the form of notes, sketches, drawings, flow charts, electronic files, laboratory notebooks, reports or
any other format that may be specified by the Company. The records shall at all times be the
sole and exclusive property of the Company and Employee agrees
not to remove such records from the Company’s premises, except as may be expressly permitted
by the Company in its written policies or by its prior written consent.

 

		(g)	Representations and Warranties.

 

(1)     No Conflicts.
Employee hereby represents and warrants that Employee is not subject to any obligation to others which would be inconsistent with
any provision of this Agreement, including with respect to any Pre-existing Intellectual Property Rights, and that
Employee has the right to grant the license granted pursuant to this Agreement.

 

(2)     No Infringement.
 Employee hereby represents and warrants, to Employee’s knowledge, all Pre-existing Intellectual Property licensed
to the Company pursuant to this Agreement does not and all Work Product will not infringe, misappropriate, dilute or otherwise
violate any third party’s Intellectual Property Rights or other rights; provided that Employee
shall not be liable for any infringement, misappropriation, dilution or other violations to the extent arising out of any instructions
or materials supplied to Employee by the Company.

 

     

     

    

 

(h)          Further
Assurances; Power of Attorney. During and after the period of this Agreement,
Employee agrees to reasonably cooperate with the Company at the Company’s expense to
(i) apply for, obtain, perfect and transfer to the Company the Work Product as well as any and all Intellectual Property Rights in
the Work Product in any jurisdiction throughout the world and (ii) maintain, protect and enforce the same, including, without
limitation, giving testimony and executing and delivering to the Company any and all applications, oaths, declarations, affidavits,
waivers, assignments and other documents and instruments as shall be requested by the Company. Employee hereby
irrevocably grants the Company power of attorney to execute and deliver any such documents on Employee’s
behalf in its name and to do all other lawfully permitted acts to transfer the Work Product to the Company and further the transfer,
prosecution, issuance and maintenance of all Intellectual Property Rights therein, to the full extent permitted
by law, if Employee does not promptly cooperate with the Company’s request (without limiting the rights the Company
shall have in such circumstances by operation of law). This power of attorney is coupled with an interest and shall not be affected
by Employee’s subsequent incapacity.

 

(i)           Moral
Rights. To the extent any copyrights are assigned under this Section, Employee hereby
irrevocably waives in favor of the Company, to the extent permitted by applicable law, any and all claims Employee may now or hereafter
have in any jurisdiction to all rights of paternity, integrity, disclosure and withdrawal and any other rights that
may be known as “moral rights” in relation to all works of authorship to which the assigned copyrights apply.

 

(j)           No
Conflict of Interest. During the term of this Agreement,
Employee will not undertake any obligation inconsistent with the terms of this Agreement unless Employee receives prior express
written or electronic authorization from the Company.  Employee warrants that there is no other contract or duty on the part
of Employee that conflicts with or is inconsistent with this Agreement.  This paragraph does not prevent Employee from performing
the same or similar services for clients other than Company so long as the clients are not direct competitors of the Company and
so long as such services do not directly or indirectly conflict with Employee’s obligations under this Agreement. A “direct
competitor” of the Company for purposes of this Agreement is defined as any individual, partnership, corporation and/or
other business entity that engages in the business of the Company.

 

		10)	Confidential Information

 

(a)          During the course of this
Agreement, from time to time, Employee is likely to obtain knowledge of trade secrets and other confidential information with regard
to the business and financial affairs of the Company and its subsidiaries (together the “Group”) and its customers’
and suppliers’ details (the “Confidential Information”). Accordingly, Employee shall not (except in the proper
course of the Services hereunder) during this Agreement, and at any time thereafter (such obligation continuing indefinitely),
divulge any Confidential Information to any person, firm, corporation, or entity whomsoever other than as required by law or legal
or similar proceedings, or as required to conduct the duties and responsibilities set forth in this Agreement. Employee shall use
best endeavors to prevent the unauthorized publication or disclosure of Confidential Information, and shall not use for Employee’s
own purposes, or for any purposes other than those of the Company Confidential Information (which may come to Employee’s
knowledge during or in the course of this Agreement hereunder or as a result of Employee’s engagement by any subsidiary of
the Company). Such Confidential Information shall, without limitation, be deemed to include the following:

 

     

     

    

 

(1)     Any knowledge or information
relating to any trade secret, process, invention, or concerning the business or finances of the Group or any dealings relating
thereto;

 

(2)      Transactions or affairs
of any of the Group, or of any officers, directors, shareholders, or employees of the Group, or any other information of a confidential
character (including such information belonging to or relating to any third party);

 

(3)     Any information concerning
the structure and format of the Group’s products, promotions, and services;

 

(4)     Any confidential business
methods of the Group;

 

(5)     Any confidential pricing
information or any information relating to prospective or actual tenders for contracts with prospective or actual suppliers or
customers of the Group;

 

(6)     Any confidential client
or customer lists of the Group; and

 

(7)     Any document or data of
the Group marked confidential or which Employee might reasonably expect to be of a confidential nature.

 

(b)    All articles, notes, sketches,
computer programs, plans, memoranda, records, and any other documents (whether in hard or electronic form) or copies thereof provided
to, created or used by Employee in relation to any Confidential Information shall be and remain the property of the Company, or
the relevant subsidiary of the Company, and shall be delivered together with all copies thereof, to the Company or as it shall
direct from time-to-time, on demand or immediately when Employee ceases to be engaged by the Company.

 

     

     

    

 

(c)    The obligations in this
Section shall not apply to information that is in the public domain other than by reason of breach of this Section.

 

(d)   Employee obligations under
this Section shall, with respect to each subsidiary of the Company, constitute a separate and distinct covenant in respect of which
Employee hereby covenants with the Company as trustee for each such other company.

 

(e)    Each of the sub-paragraphs
of this Section shall be separate, distinct, and severable from each other. In the event that any of the sub-paragraphs is held
void but would be valid if any part of the wording thereof were deleted, such restriction shall apply with such deletions as may
be necessary to make it valid and effective.

 

		11)	This Agreement shall be governed by and construed in accordance with the laws of the United States, and specifically the laws
of the state of California. Should a dispute arise, both parties shall subject themselves to exclusive jurisdiction of the courts
of the state of California.

 

		12)	This Agreement constitutes the entire understanding between the Parties relating to its subject matter, superseding all negotiations,
prior discussions, preliminary agreements and agreements relating to the subject matter hereof made prior to the date hereof. No
waiver by a Party of any breach by another Party of any term, provision or condition of this Agreement to be performed by such
other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or at any prior or subsequent
time. This Agreement may not be modified or amended except in writing signed by the Parties. Each of the Parties hereto agrees
that this Agreement has been jointly prepared, and that no claim may be asserted by any Party that any ambiguity in this Agreement
may be construed against any one Party. Except as expressly herein amended, all of the terms and conditions of this Agreement shall
continue in full force and effect, and the same are hereby ratified and confirmed.

 

		13)	This Agreement may be executed in counterparts, each of which shall constitute an original but together shall constitute one
and the same Agreement. The Parties further agree that such counterparts may be provided via scan, email, and/or facsimile to one
another, each of which shall be binding upon the signatory who sends the scan, email and/or facsimile that was signed by such sending
signatory. The Parties further agree to exchange the original signature pages hereof as soon as practicable after sending such
scan, email and/or facsimile, but in any dispute or controversy, the Parties hereto agree that it shall not be necessary for any
such Party to provide the original signature pages of the other as a condition of enforcing this Agreement, it being understood
that such scan, email and/or facsimile signature pages shall be sufficient to establish the consent of the Party who sent the scan,
email and/or facsimile that was signed by such sending signatory to be bound by the terms of this Agreement.

 

     

     

    

 

IN WITNESS WHEREOF the parties have executed
this Agreement effective as of this 6th day of February 2017.

 

OPIANT PHARMACEUTICALS, INC.

 

	By:	/s/ Roger Crystal	 
	Name: 	Roger Crystal	 
	Title:	Chief Executive Officer	 

 

	By:	PHIL SKOLNICK	 
	Name: 	/s/Phil Skolnick	 
	Title:	Chief Scientific Officer	 

 

     

     

    

 

EXHIBIT A

 

OPIANT PHARMACEUTICALS, INC.

401 Wilshire Blvd., 12th Floor

Santa Monica, CA 90401

 

Form of Notice of Stock Option Grant

 

Dear Phil Skolnick,

 

Pursuant
to the Employment Agreement between Opiant Pharmaceuticals, Inc. (the “Company”) and you effective February
6, 2017 (the “Employment Agreement”), the Company has granted
you options (the “Options”) to purchase common stock of the Company (the “Common Stock”) (with each share
of Common Stock, a “Share”) as follows:

 

	Board Approval Date:	[                  ], 2017
	 	 
	Date of Grant:	February 6, 2017
	 	 
	Exercise Price per Share:	US$[          ], which shall be equal to or greater than the fair market value of a Share of Common Stock on the Date of Grant.
	 	 
	Total Number of Shares Granted:	200,000
	 	 
	Method of Exercise:	Cashless exercise
	 	 
	Type of Options:	Non-Qualified Stock Options
	 	 
	Expiration Date:	February  5, 2027

 

	Termination Period:	Except as otherwise provided below, these Options may be exercised for a period of ten (10) years from the Date of Grant.  You are responsible for keeping track of these exercise periods in the event you no longer are employed by the Company.  The Company will not provide further notice of such periods.

 

	 	Notwithstanding anything herein to the contrary, these Options shall expire on the day that is the earlier of: (a) ninety (90) calendar days after Employee ceases to provide Services (as defined in the Employment Agreement”) pursuant to the Employment Agreement, (b) ninety (90) calendar days after the Extended Term (as defined in the Employment Agreement), to the extent it is applicable, ends, (c) ninety (90) calendar days after the Term (as defined in the Employment Agreement) ends if there is no Extended Term (as defined in the Employment Agreement), (d) Employee becomes subject to a termination or fundamental transaction pursuant to Paragraph 7 of the Employment Agreement, or (e) ten (10) years from the date of issuance of such Options.

 

     

     

    

 

	Transferability:	These Options may not be transferred, except upon your death or as permitted by applicable laws and regulations.

 

	Restriction on Exercise:	None, except as provided herein.

 

	Vesting:	One hundred thousand (100,000) of these Options shall vest on the eighteenth month anniversary of the issue date of the Options.  Five thousand five hundred fifty-five (5,555) of these Options shall vest on each of the nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth and twenty-sixth anniversaries of the Effective Date (as defined in the Employment Agreement).  Five thousand five hundred fifty-six (5,556) of these Options shall vest on each of the twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, thirty-fifth and thirty-sixth anniversaries of the Effective Date (as defined in the Employment Agreement).

 

	Death:	Notwithstanding anything herein to the contrary, in the event of your death, all exercisable Options may be exercised by your estate (or as may otherwise be provided for by you) at any time prior to the expiration date of the term of the Options.

 

     

     

    

 

	Fundamental Transaction:	Unless the Board of Directors of the Company (the “Board”) shall reasonably determine otherwise in good faith, in the event that the Company effects a Fundamental Transaction (as defined below), any outstanding Options shall be fully exercisable regardless of the vesting and exercise schedule otherwise applicable to such Options.  You shall have the right to receive the consideration per Share receivable by other holders of Shares of Common Stock as a result of such Fundamental Transaction.  If holders of Shares of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction with respect to the Shares, then you shall be given the same choice.   

 

	 	Notwithstanding the foregoing, in the event of a Fundamental Transaction and if the Board may reasonably determine in good faith, the Options may be (i) honored or assumed, or new rights substituted therefore (such honored, assumed or substituted award hereinafter called an “Alternative Award”), by the Company or its affiliates or any successor entity in the Fundamental Transaction immediately following the Fundamental Transaction; provided that any such Alternative Award must provide you with (a) rights and entitlements substantially equivalent to or better than the rights, terms and conditions applicable under the Options and (b) substantially equivalent value to such Options (determined at the time of the Fundamental Transaction); or (ii) purchased by the Company by paying to you an amount of cash equal to the value of the remaining unexercised portion of the Options on the date of the consummation of such Fundamental Transaction to be determined by a reasonable method selected by the Board in good faith.  In the event that a successor entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of the Options referring to the “Company” shall refer instead to the successor entity) the Company, such successor entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under Options with the same effect as if such successor entity had been named as the Company therein.

 

     

     

    

 

	 	For purposes of this provision, the term “Fundamental Transaction” shall mean the Company, directly or indirectly, in one or more related transactions effects, complete or consummates, as applicable any (i) merger or consolidation of the Company with or into another person, or (ii) reclassification, reorganization or recapitalization of the Common Stock or any compulsory Share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, (iii) sale, lease, license, assignment, transfer, conveyance or other disposition of 50% or more of its assets, (iv) purchase offer, tender offer or exchange offer (whether by the Company or another person) pursuant to which holders of Common Stock are permitted to sell, tender or exchange their Shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, or (v) stock or Share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding Shares of Common Stock (not including any Shares of Common Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making or party to, such stock or Share purchase agreement or other business combination).

 

	Adjustments:	If there is any change in the number or kind of Shares of Common Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of Shares, (ii) by reason of a merger, reorganization or consolidation, (iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding stock as a class without the Company’s receipt of consideration, or if the value of outstanding Shares of stock is substantially reduced as result of a spinoff or the Company’s payment of any extraordinary dividend or distribution, the kind and number of Shares covered by, or to be issued or issuable under, any outstanding Options and the price per Share or the applicable market value of such Options shall be required to be equitably adjusted by the Company to reflect any increase or decrease in the number of, or change in the kind or value of, issued Shares to preclude, to the extent practicable, the enlargement or dilution of rights and benefits such outstanding Options; provided, however, than any fractional Shares resulting from such adjustment shall be eliminated.  Any adjustments to outstanding Options shall be consistent with Section 409A of the Internal Revenue Code, to the extent applicable.  The adjustments of Options hereunder shall include adjustment of Shares, Exercise Price, or other terms and conditions, as the Company deems appropriate so long as the Company acts in good faith and in a fair and reasonable manner.  Any adjustments determined by the Company shall be final, binding and conclusive so long as the Company acts in good faith and in a fair and reasonable manner.

 

     

     

    

 

Following receipt by
the Company of evidence and/or an indemnity from you to the Company in a form reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of these Options or any certificates for representing the Shares underlying these Options and,
in the event of mutilation, following the surrender and cancellation of such Options or stock certificate, the Company will make
and deliver replacement Options or stock certificate of like tenor and dated as of such cancellation, in lieu of these Options
or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement Options
or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Options or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Options and any Shares underlying these Options. Subject
to the restrictions and requirements of applicable law, these Options are exchangeable at any time for an equal aggregate number
of options of different denominations, as reasonably requested by you surrendering the same, or in such denominations as may be
requested by you (but not exceeding the number of Shares underlying the Options in these Options in the aggregate).  No service
charge will be made for such registration or transfer, exchange or reissuance.

 

Upon the exercise of
these Options, the fair market value per Share shall be equal to the closing price of the Shares on the day prior to such exercise.
Exercise of these Options shall occur by your: (i) surrendering the exercised Options at the principal office of the Company together
with a properly completed and signed Notice of Exercise of Stock Option (as per Exhibit B), and (ii) providing via email a readable
..pdf or scan of all of the documentation set forth in (i) to the email addresses of the Chief Executive Officer, Chief Financial
Officer and Controller (if the Company has a Controller at such time) of the Company at the time of such surrender (the current
applicable email addresses being: rcrystal@opiant.com and kpollack@opiant.com).

 

     

     

    

 

Upon exercise of these
Options pursuant to the terms of the prior paragraph, the number of Shares of Common Stock to be issued to you shall be computed
using the following formula:

 

	X =	Y(A-B)	 
	 	A	 

 

	Where X =	the number of Shares of Common Stock to be issued to you
	 	 
	Y =	the number of Shares of Common Stock purchasable under the Options or, if only a portion of the Options are being exercised, the portion of the Options being exercised (at the date of such calculation)
	 	 
	A =	the closing price of one Share of the Common Stock on the day prior to such exercise (as adjusted to the date of such calculation)
	 	 
	B =	the Exercise Price per Share (as adjusted to the date of such calculation)

 

These Options may be
delivered to you electronically with a scanned signature, in which case they shall have the same effect and force as if they had
been delivered in original signed form.

 

By your signature and
the signature of the Company’s representative below, you and the Company agree to the terms of these Options.

 

	 	 	OPIANT PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	 	Kevin Pollack, Chief Financial Officer

 

     

     

    

 

EXHIBIT B

 

Form of Notice of Exercise of Stock
Option

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the stock Option(s) granted to me by Opiant Pharmaceuticals, Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per Share (equal to the closing price of the
Shares of Common Stock of the Company on the day prior to this exercise). Pursuant to the terms of such Option(s), I wish to purchase
_______________ Shares of the Common Stock covered by such Option(s) at the Exercise Price(s) of US$ ______ per Share via cashless
exercise.

 

These Shares should be delivered as follows:

 

	Name:	 	 	 
	 	 	 	 
	Address:	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	Social Security Number:	 	 	 

 

I represent that I will not dispose of such
Shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Name:	 	 
	 	 	 	 	 	 
	 	 	 	Email:	 	 
	 	 	 	 	 	 
	 	 	 	Phone: 	 	 

 

     

     

    

 

EXHIBIT
C

 

LIST
OF PRE-EXISTING INTELLECTUAL PROPERTY RIGHTS

 

Unregistered Intellectual Property 

 

	 Title	 Brief Description	 Date

 

Registered
Intellectual Property

 

	Jurisdiction	 	Name or

Title	 	Status

(Pending or

Registered)	 	Registration or

Application

Serial Number	 	Registration or

Application

Date
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

þ
No Pre-existing Intellectual Property Rights

 

 ̈
Additional Sheets Attached

 

Signature of behalf
of the Consultancy: _____________________________

 

Print Name: ____________________________

 

Date: ______________Exhibit 4.1

 

NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT (AS DEFINED HEREIN), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA
FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

real
goods solar, INC.

 

Warrant
To Purchase Common Stock

 

Warrant No.: WPA6-1

Number of Shares of Common Stock: 185,500

Date of Issuance: February 6, 2017 (“Issuance Date”)

 

Real Goods Solar, Inc.,
a Colorado corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, ROTH CAPITAL PARTNERS, LLC, the
registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth
below, to purchase from the Company, at the Exercise Price (as defined in Section 1(b)) then in effect, at any time or times on
or after the date hereof (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on the
Expiration Date, up to such number of fully paid and nonassessable shares of Common Stock equal to 185,500, subject to adjustment
as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this
Warrant to Purchase Common Stock (including any warrants to purchase Common Stock issued in exchange, transfer or replacement hereof,
this “Warrant”), shall have the meanings set forth in Section 17. This Warrant is one of the Placement Agent
Warrants (the “PA Warrants”) issued pursuant to Section 1 of the Placement Agency Agreement, dated as of February
1, 2017 (the “Subscription Date”), by and between the Company and Roth Capital Partners, LLC (the “Placement
Agency Agreement”).

 

     

     

    

 

1.           EXERCISE
OF WARRANT.

 

(a)          Mechanics
of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section
1(f)), this Warrant may be exercised by the Holder at any time or times on or after the Initial Exercisability Date, in whole or
in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”),
of the Holder’s election to exercise this Warrant and (ii) (A) payment to the Company of an amount equal to the applicable
Exercise Price (as defined in Section 1(b)) multiplied by the number of Warrant Shares as to which this Warrant is being exercised
(the “Aggregate Exercise Price”) in cash by wire transfer of immediately available funds or (B) if the provisions
of Section 1(d) are applicable, by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as
defined in Section 1(d)). The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder.
Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as
cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant
Shares. No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Exercise Notice be required. Execution and delivery of an Exercise Notice for all of the then remaining Warrant Shares shall
have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in accordance with the
terms hereof. On or before the first (1st) Trading Day following the date on which the Company has received the Exercise
Notice, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder
and the Company’s transfer agent (the “Transfer Agent”). On or before the earlier of (i) the third (3rd)
Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, following the date on which the Company
has received the Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise)
on or prior to the second (2nd) Trading Day following the date on which the Company has received the Exercise Notice (the “Share
Delivery Date”) (provided that if the Aggregate Exercise Price has not been delivered by such date, the Share Delivery
Date shall be one (1) Trading Day after the Aggregate Exercise Price (or notice of a Cashless Exercise) is delivered), the Company
shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated
Securities Transfer Program and the Holder may sell the Warrant Shares without restriction or limitation either (I) pursuant to
Rule 144 of the 1933 Act and without the requirement to be in compliance with Rule 144(c)(1) of the 1933 Act or (II) pursuant to
an effective registration statement registering the Warrant Shares for issuance, credit such aggregate number of Warrant Shares
to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC
through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated
Securities Transfer Program, or if the Holder may not sell the Warrant Shares without restriction or limitation either (I) pursuant
to Rule 144 of the 1933 Act and without the requirement to be in compliance with Rule 144(c)(1) of the 1933 Act or (II) pursuant
to an effective registration statement registering the Warrant Shares for issuance, issue and dispatch by overnight courier to
the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company
agrees to maintain a transfer agent that is a participant in the DTC Fast Automated Securities Transfer Program so long as this
Warrant remains outstanding and exercisable. The Company shall be responsible for all fees and expenses of the Transfer Agent and
all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any. Upon delivery of the Exercise Notice, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or
the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is submitted in connection
with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise
is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and
in no event later than three (3) Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with
Section 7(d)) representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under
this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional Warrant Shares are
to be issued upon the exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded up to the
nearest whole number. The Company shall pay any and all taxes (other than the Holder’s income taxes) which may be payable
with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. The Company’s obligations to issue
and deliver Warrant Shares in accordance with the terms and subject to the conditions hereof are absolute and unconditional, irrespective
of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination.
 

 

(b)          Exercise
Price. For purposes of this Warrant, “Exercise Price” means $3.875, subject to adjustment as provided
herein.

 

    	 	- 2 -	 

     

    

 

(c)          Company’s
Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason, in the manner required by
Section 1(a), to issue to the Holder on or prior to the Share Delivery Date if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, a certificate for the number of shares of Common Stock to which the Holder is entitled
and register such shares of Common Stock on the Company’s share register or if the Transfer Agent is participating in the
DTC Fast Automated Securities Transfer Program, to credit the Holder’s balance account with DTC, for such number of shares
of Common Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant, and if on or after the Share
Delivery Date the Holder (or any other Person in respect, or on behalf, of the Holder) purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of
shares of Common Stock equal to or any portion of the number of shares of Common Stock issuable upon such exercise that the Holder
anticipated receiving from the Company (a “Buy-In”), then, in addition to all other remedies available to the
Holder, the Company shall, within three (3) Trading Days after the Holder’s request and in the Holder’s discretion,
either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In Price”),
at which point the Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) or credit
such Holder’s balance account with DTC for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation
to deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit such Holder’s balance
account with DTC, as applicable, and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over
the product of (A) such number of shares of Common Stock, times (B) any trading price of the Common Stock selected by the Holder
in writing as in effect at any time during the period beginning on the date of the applicable Exercise Notice and ending on the
date of such issuance and payment under this Section 1(c). Nothing shall limit the Holder’s right to pursue any other remedies
available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive
relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock (or to electronically
deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.  

 

(d)          Cashless
Exercise.  At any time following the Issuance Date, the Holder may, in its sole discretion, exercise this Warrant
in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise
in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares
of Common Stock determined according to the following formula (a “Cashless Exercise”):

 

Net Number
= (A x B) - (A x C)

D

 

For purposes
of the foregoing formula:

 

A= the
total number of shares with respect to which this Warrant is then being exercised.

 

B= the
arithmetic average of the Closing Sale Prices of the Common Stock for the five (5) consecutive Trading Days ending on the date
immediately preceding the date of the Exercise Notice.

 

C= the
Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

D= the
Closing Sale Price of the Common Stock on the date of the Exercise Notice.

 

If Warrant Shares are
issued in a Cashless Exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the 1933 Act, the Warrant
Shares shall take on the registered characteristics of the Warrant being exercised, and the holding period of the Warrant being
exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to
this Section 1(d).

 

(e)          Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with Section 12.

 

    	 	- 3 -	 

     

    

 

(f)          Beneficial
Ownership Limitation on Exercises. Notwithstanding anything to the contrary contained herein, the Company shall not effect
the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant
to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent
that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially
own in excess of 4.99% (the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately
after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially
owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and
all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to
which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution
Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including,
without limitation, any convertible notes or convertible preferred stock or warrants) beneficially owned by the Holder or any other
Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(f).
For purposes of this Section 1(f), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities
Exchange Act of 1934, as amended (the “1934 Act”). For purposes of this Warrant, in determining the number of
outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage,
the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual
Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange
Commission (the “SEC”), as the case may be, (y) a more recent public announcement by the Company or (3) any
other written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding (the “Reported
Outstanding Share Number”). If the Company receives an Exercise Notice from the Holder at a time when the actual number
of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder
in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise
cause the Holder’s beneficial ownership, as determined pursuant to this Section 1(f), to exceed the Maximum Percentage, the
Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number
of shares by which such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable,
the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time,
upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or
by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was
reported. In the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder
and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number
of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which
the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the
“Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have
the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has
been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares.
Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage
to any other percentage not in excess of 9.99% as specified in such notice; provided, however, that (i) any such
increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered
to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to
any other holder of PA Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock
issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned
by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f)
to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with
the intended beneficial ownership limitation contained in this Section 1(f) or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor
holder of this Warrant.

 

    	 	- 4 -	 

     

    

 

(g)          Insufficient
Authorized Shares. If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized
and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least
a number of shares of Common Stock equal to the maximum number of shares of Common Stock as shall from time to time be necessary
to effect the exercise of all of this Warrant then outstanding (the “Required Reserve Amount” and the failure
to have such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized Share Failure”),
then the Company shall promptly take all action reasonably necessary to increase the Company’s authorized shares of Common
Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant and the other PA Warrants
then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence
of an Authorized Share Failure, but in no event later than seventy-five (75) days after the occurrence of such Authorized Share
Failure, the Company shall either (x) obtain the written consent of its shareholders for the approval of an increase in the number
of authorized shares of Common Stock and provide each shareholder with an information statement with respect thereto or (y) hold
a meeting of its shareholders for the approval of an increase in the number of authorized shares of Common Stock. In connection
with such meeting, the Company shall provide each shareholder with a proxy statement and shall use its reasonable best efforts
to solicit its shareholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors
to recommend to the shareholders that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized
Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding Common
Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining
such consent and submitting for filing with the SEC an Information Statement on Schedule 14C. The initial number of shares of Common
Stock reserved for exercise of this Warrant and the other PA Warrants and each increase in the number of shares so reserved shall
be allocated pro rata among the Holder and the holders of the other PA Warrants, based on the number of shares of Common Stock
issuable upon exercise of this Warrant (without regard to any limitations in exercise) issued to the Holder on the Issuance Date
(the “Authorized Share Allocation”). In the event that the Holder shall sell or otherwise transfer this Warrant,
each transferee shall be allocated a pro rata portion of such holder’s Authorized Share Allocation. Any shares of Common
Stock reserved and allocated to any Person which ceases to hold any PA Warrants shall be allocated to the Holder and the remaining
holders of PA Warrants, pro rata based on the shares of Common Stock issuable upon exercise of the PA Warrants then held by such
holders (without regard to any limitations on the exercise of the PA Warrants).

 

2.           ADJUSTMENT
OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from
time to time as follows:

 

(a)          Voluntary
Adjustment By Company. The Company may at any time during the term of this Warrant, with the prior written consent of the Required
Holders, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.

 

(b)          Adjustment
Upon Subdivision or Combination of Shares of Common Stock. If the Company at any time on or after the Subscription Date subdivides
(by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock
into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced
and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date
combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into
a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased
and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(b) shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

(c)          Other
Events. If any event occurs of the type contemplated by the provisions of this Section 2, but not expressly provided for by
such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights
with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and
the number of Warrant Shares, as mutually determined by the Company’s Board of Directors and the Required Holders, so as
to protect the rights of the Holder; provided, however, that no such adjustment pursuant to this Section 2(c) will
increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.

 

    	 	- 5 -	 

     

    

 

3.           RIGHTS
UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) but not including any
dividend in the form of cash declared on the Common Stock generally (a “Distribution”), at any time after the
issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same
extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without
limitation, the Maximum Percentage) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, that to the extent that the Holder’s right to participate in any such
Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall
not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares
of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder
and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution
(and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance)
to the same extent as if there had been no such limitation).

 

4.           PURCHASE
RIGHTS; FUNDAMENTAL TRANSACTIONS.

 

(a)          Purchase
Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues or sells any
Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would
result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such shares of Common
Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall
be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder
and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right
(and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly
in abeyance) to the same extent as if there had been no such limitation).

 

    	 	- 6 -	 

     

    

 

(b)          Fundamental
Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes
in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 4(b) pursuant
to written agreements in form and substance reasonably satisfactory to the Required Holders and approved by the Required Holders,
such approval not to be unreasonably withheld or delayed, prior to such Fundamental Transaction, including agreements, if so requested
by the Holder, to deliver to each holder of the PA Warrants in exchange for such PA Warrants a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an
adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction,
and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and satisfactory to the Required Holders, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price
being for the purpose of protecting the economic value of this Warrant immediately prior to the occurrence or consummation of such
Fundamental Transaction). Upon the occurrence or consummation of any Fundamental Transaction, and it shall be a required condition
to the occurrence or consummation of any Fundamental Transaction that, the Company and the Successor Entity or Successor Entities,
jointly and severally, shall succeed to, and the Company shall cause any Successor Entity or Successor Entities to jointly and
severally succeed to, and be added to the term “Company” under this Warrant (so that from and after the date of such
Fundamental Transaction, and the provisions of this Warrant referring to the “Company” shall refer instead to each
of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Company and the Successor Entity
or Successor Entities, jointly and severally, may exercise every right and power of the Company prior thereto and shall assume
all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor
Entity or Successor Entities, jointly and severally, had been named as the Company in this Warrant, and, solely at the request
of the Holder, if the Successor Entity and/or Successor Entities is a publicly traded corporation whose common stock is quoted
on or listed for trading on an Eligible Market, shall deliver (in addition to and without limiting any right under this Warrant)
to the Holder in exchange for this Warrant a security of the Successor Entity and/or Successor Entities evidenced by a written
instrument substantially similar in form and substance to this Warrant and exercisable for a corresponding number of shares of
capital stock of the Successor Entity and/or Successor Entities (the “Successor Capital Stock”) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction (such corresponding number of shares of Successor Capital Stock to be delivered
to the Holder shall be equal to the greater of (A) the quotient of (i) the aggregate dollar value of all consideration (including
cash consideration and any consideration other than cash (“Non-Cash Consideration”), in such Fundamental Transaction,
as such values are set forth in any definitive agreement for the Fundamental Transaction that has been executed at the time of
the first public announcement of the Fundamental Transaction or, if no such value is determinable from such definitive agreement,
as determined in accordance with Section 12 with the term “Non-Cash Consideration” being substituted for the term “Exercise
Price”) that the Holder would have been entitled to receive upon the happening of such Fundamental Transaction or the record,
eligibility or other determination date for the event resulting in such Fundamental Transaction, had this Warrant been exercised
immediately prior to such Fundamental Transaction or the record, eligibility or other determination date for the event resulting
in such Fundamental Transaction (without regard to any limitations on the exercise of this Warrant) (the “Aggregate Consideration”)
divided by (ii) the per share Closing Sale Price of such Successor Capital Stock on the Trading Day immediately prior to the consummation
or occurrence of the Fundamental Transaction and (B) the product of (i) the Aggregate Consideration and (ii) the highest exchange
ratio pursuant to which any shareholder of the Company may exchange Common Stock for Successor Capital Stock) (provided,
however, that to the extent that the Holder’s right to receive any such shares of publicly traded common stock (or
their equivalent) of the Successor Entity would result in the Holder and its other Attribution Parties exceeding the Maximum Percentage,
if applicable, then the Holder shall not be entitled to receive such shares to such extent (and shall not be entitled to beneficial
ownership of such shares of publicly traded common stock (or their equivalent) of the Successor Entity as a result of such consideration
to such extent) and the portion of such shares shall be held in abeyance for the Holder until such time or times, as its right
thereto would not result in the Holder and its other Attribution Parties exceeding the Maximum Percentage, at which time or times
the Holder shall be delivered such shares to the extent as if there had been no such limitation), and such security shall be reasonably
satisfactory to the Holder, and with an identical exercise price to the Exercise Price hereunder (such adjustments to the number
of shares of capital stock and such exercise price being for the purpose of protecting after the consummation or occurrence of
such Fundamental Transaction the economic value of this Warrant that was in effect immediately prior to the consummation or occurrence
of such Fundamental Transaction, as elected by the Holder solely at its option). Upon occurrence or consummation of the Fundamental
Transaction, and it shall be a required condition to the occurrence or consummation of such Fundamental Transaction that, the Company
and the Successor Entity or Successor Entities shall deliver to the Holder confirmation that there shall be issued upon exercise
of this Warrant at any time after the occurrence or consummation of the Fundamental Transaction, as elected by the Holder solely
at its option, shares of Common Stock, Successor Capital Stock or, in lieu of the shares of Common Stock or Successor Capital Stock
(or other securities, cash, assets or other property purchasable upon the exercise of this Warrant prior to such Fundamental Transaction),
such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription
rights), which for purposes of clarification may continue to be shares of Common Stock, if any, that the Holder would have been
entitled to receive upon the happening of such Fundamental Transaction or the record, eligibility or other determination date for
the event resulting in such Fundamental Transaction, had this Warrant been exercised immediately prior to such Fundamental Transaction
or the record, eligibility or other determination date for the event resulting in such Fundamental Transaction (without regard
to any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. In addition
to and not in substitution for any other rights hereunder, prior to the occurrence or consummation of any Fundamental Transaction
pursuant to which holders of shares of Common Stock are entitled to receive securities, cash, assets or other property with respect
to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision
to ensure that, and any applicable Successor Entity or Successor Entities shall ensure that, and it shall be a required condition
to the occurrence or consummation of such Corporate Event that, the Holder will thereafter have the right to receive upon exercise
of this Warrant at any time after the occurrence or consummation of the Corporate Event, shares of Common Stock or Successor Capital
Stock or, if so elected by the Holder, in lieu of the shares of Common Stock (or other securities, cash, assets or other property)
purchasable upon the exercise of this Warrant prior to such Corporate Event (but not in lieu of such items still issuable under
Sections 3 and 4(a), which shall continue to be receivable on the Common Stock or on the such shares of stock, securities, cash,
assets or any other property otherwise receivable with respect to or in exchange for shares of Common Stock), such shares of stock,
securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights and any
shares of Common Stock) which the Holder would have been entitled to receive upon the occurrence or consummation of such Corporate
Event or the record, eligibility or other determination date for the event resulting in such Corporate Event, had this Warrant
been exercised immediately prior to such Corporate Event or the record, eligibility or other determination date for the event resulting
in such Corporate Event (without regard to any limitations on exercise of this Warrant). Provision made pursuant to the preceding
sentence shall be in a form and substance reasonably satisfactory to the Holder. The provisions of this Section 4(b) shall apply
similarly and equally to successive Fundamental Transactions and Corporate Events. Notwithstanding the foregoing, the Holder may
elect, in its sole discretion, by delivery of written notice to the Company, to waive this Section 4(b) and allow the Company to
enter into or be a party to a Fundamental Transaction without the assumption of this Warrant pursuant to the provisions of this
Section 4(b), provided, however, that any such waiver shall only bind the Holder with respect to this Warrant and
not the Holder with respect to any other warrant or other securities of the Company or any holder of other PA Warrants.

 

    	 	- 7 -	 

     

    

 

(c)          Notwithstanding
anything herein to the contrary, the Company shall be required to obtain the prior written consent of the Required Holders to enter
into, allow and/or consummate a Fundamental Transaction other than one in which a Successor Entity that is a publicly traded corporation
whose stock is quoted or listed for trading on an Eligible Market assumes this Warrant such that the Warrant shall be exercisable
for the publicly traded Common Stock of such Successor Entity.

 

5.           NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation or Bylaws, or
through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will
at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the
rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of
any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall
take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the PA Warrants are
outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock,
solely for the purpose of effecting the exercise of the PA Warrants, the Required Reserve Amount to effect the exercise of the
PA Warrants then outstanding (without regard to any limitations on exercise).

 

6.           WARRANT
HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital
of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in
such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote,
give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to
the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.
In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company
or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices
and other information given to the shareholders of the Company generally, contemporaneously with the giving thereof to the shareholders.

 

    	 	- 8 -	 

     

    

 

7.           REISSUANCE
OF WARRANTS.

 

(a)          Transfer
of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company
will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the
Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less
than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section
7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

(b)          Lost,
Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by
the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the
Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase
the Warrant Shares then underlying this Warrant.

 

(c)          Exchangeable
for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the
Company, for a new warrant or warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the
number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion
of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no PA
Warrants for fractional Warrant Shares shall be given.

 

(d)          Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to
purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a)
or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying
the other new warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this
Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date,
and (iv) shall have the same rights and conditions as this Warrant.

 

8.           NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with Section 10 of the Placement Agency Agreement. The Company shall provide the Holder with prompt written notice of all actions
taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting
the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the
Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen
(15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution
upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights
to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights to
vote with respect to any Fundamental Transaction, dissolution or liquidation; provided, however, in each case that
such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. It
is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice shall be definitive
and may not be disputed or challenged by the Company.

 

9.           AMENDMENT
AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and the Company may
take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Holder.

 

    	 	- 9 -	 

     

    

 

10.         GOVERNING
LAW; JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of
the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City
of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Company hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to the Company at the address set forth in Section 10 of the Placement Agency Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from
bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations
to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court
ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED
HEREBY.

 

11.         CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and all the Holders and shall not be construed
against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part
of, or affect the interpretation of, this Warrant.

 

12.         DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile or electronic mail within
two (2) Business Days after receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the
Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within
three (3) Business Days after such disputed determination or arithmetic calculation being submitted to the Holder, then the Company
shall, within two (2) Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent,
reputable investment bank selected by the Holder and approved by the Company, such approval not to be unreasonably withheld or
delayed or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant,
approved by the Holder, such approval not to be unreasonably withheld or delayed. The Company shall cause at its expense the investment
bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder
of the results no later than ten (10) Business Days from the time it receives the disputed determinations or calculations. Such
investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties
absent demonstrable error.

 

13.         REMEDIES,
OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition
to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company
to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that,
in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available
remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other
security being required.

 

14.         TRANSFER.
       This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged
or assigned without the consent of the Company, subject to compliance with all applicable state and federal securities laws; provided,
however, that neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would
result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the
date of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer
of any security: (i) by operation of law or by reason of reorganization of the Company; (ii) to any FINRA member firm participating
in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction
in this Section 14 for the remainder of the time period; (iii) if the aggregate amount of securities of the Company held by the
Holder or related person do not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis
by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by
the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or
conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 14 for the remainder
of the time period. The Holder, by acceptance of this Warrant, will acquire the Warrant Shares issuable upon such exercise, for
its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of
the 1933 Act or any applicable state securities law, except pursuant to sales registered or exempted under the 1933 Act.

 

    	 	- 10 -	 

     

    

 

15.         SEVERABILITY.        If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of
competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to
apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision
shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to
express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be
conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or
unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the
prohibited, invalid or unenforceable provision(s).

 

16.         DISCLOSURE.
Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, unless the Company has in good
faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to the Company
or its subsidiaries, the Company shall within one (1) Business Day after any such receipt or delivery publicly disclose such material,
nonpublic information on a Current Report on Form 8-K or otherwise. In the event that the Company believes that a notice contains
material, nonpublic information relating to the Company or its subsidiaries, the Company so shall indicate to such Holder contemporaneously
with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters
relating to such notice do not constitute material, nonpublic information relating to the Company or its subsidiaries.

 

17.         CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)          “1933
Act” means the Securities Act of 1933, as amended.

 

(b)          “Affiliate”
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common
control with, such Person, it being understood for purposes of this definition that “control” of a Person means the
power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors
of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

(a)          “Attribution
Parties” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder
funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by
the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder
or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any
of the foregoing and (iv) any other Persons whose beneficial ownership of the Company’s Common Stock would or could be aggregated
with the Holder’s and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose
of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

 

(b)          “Bloomberg”
means Bloomberg Financial Markets.

 

(c)          “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.

 

    	 	- 11 -	 

     

    

 

(d)          “Closing
Sale Price” means, for any security as of any date, the last closing trade price for such security on the Principal Market,
as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing
trade price, then the last trade price of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if
the Principal Market is not the principal securities exchange or trading market for such security, the last trade price of such
security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg,
or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin
board for such security as reported by Bloomberg, or, if no last trade price is reported for such security by Bloomberg, the average
of the ask prices of any market makers for such security as reported in the OTC Link or “pink sheets” by OTC Markets
Group Inc. (formerly Pink OTC Markets Inc.). If the Closing Sale Price cannot be calculated for a security on a particular date
on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually
determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved pursuant to Section 12. All such determinations to be appropriately adjusted for
any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation
period.

 

(e)          “Common
Stock” means (i) the Company’s shares of Class A Common Stock, par value $0.0001 per share, and (ii) any
share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such
Common Stock.

 

(f)          “Convertible
Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable
or exchangeable for shares of Common Stock.

 

(g)          “Eligible
Market” means the Principal Market, the NYSE MKT LLC, The NASDAQ Global Market, The NASDAQ Global Select Market, The
New York Stock Exchange, Inc., the OTC Bulletin Board, the OTC QX or the OTC QB.

 

(h)          “Expiration
Date” means February 1, 2022, or, if such date falls on a day other than a Business Day or on which trading does not
take place on the Principal Market (a “Holiday”), the next day that is not a Holiday.

 

(i)          “Fundamental
Transaction” means (A) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or
otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving
corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of
the properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation
S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be
subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange
offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding
shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated
with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number
of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party
to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934
Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or
more Subject Entities whereby such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the
outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common
Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock
purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the
Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the
outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company shall,
directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any
Subject Entity individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as defined
in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender,
tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization,
recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner
whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock,
(y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such
Subject Entities as of the Subscription Date calculated as if any shares of Common Stock held by all such Subject Entities were
not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common
Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger
or other transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of
the shareholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one
or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to
circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition
or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction.

 

    	 	- 12 -	 

     

    

 

(j)          “Group”
means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.

 

(k)          “Options”
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

(l)          “Parent
Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity
whose common shares or common stock or equivalent equity security is quoted or listed on an Eligible Market (or, if so elected
by the Required Holders, any other market, exchange or quotation system), or, if there is more than one such Person or such entity,
the Person or such entity designated by the Required Holders or in the absence of such designation, such Person or entity with
the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

 

(m)          “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.

 

(n)          “Principal
Market” means The NASDAQ Capital Market.

 

(o)          “Required
Holders” means the holders of the PA Warrants representing at least a majority of the shares of Common Stock underlying
the PA Warrants then outstanding.

 

(p)          [RESERVED]

 

(q)          “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s
primary trading market or quotation system from time to time, with respect to trades of the Common Stock as in effect of the date
of delivery of the Exercise Notice.

 

(r)          “Subject
Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.

 

(s)          “Successor
Entity” means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the
Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

(t)          “Trading
Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the
principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common
Stock is then traded.

 

    	 	- 13 -	 

     

    

 

[Signature Page Follows]

 

    	 	- 14 -	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

	 	REAL GOODS SOLAR, INC.
	 	 	 
	 	By:	/s/ Dennis Lacey
	 	Name:	Dennis Lacey
	 	Title:	Chief Executive Officer

 

[Signature Page to Placement AgentWarrant]

 

     

     

    

 

EXHIBIT A

 

EXERCISE NOTICE

 

TO BE EXECUTED BY THE REGISTERED HOLDER
TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

 

REAL GOODS SOLAR, INC.

 

The undersigned holder
hereby exercises the right to purchase _________________ of the shares of Class A Common Stock, par value $0.0001 per share (the
“Warrant Shares”), of Real Goods Solar, Inc., a Colorado corporation (the “Company”), evidenced
by the attached Warrant to purchase Common Stock No. WPA5-____ (the “Warrant”). Capitalized terms used herein
and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

1. Form of Exercise
Price. The holder intends that payment of the Exercise Price shall be made as:

 

____________  a “Cash
Exercise” with respect to _________________ Warrant Shares; or

 

____________  a “Cashless
Exercise” with respect to _______________ Warrant Shares.

 

2. Payment of Exercise
Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued
pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance
with the terms of the Warrant.

 

3. Delivery of Warrant
Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.

 

	Please issue the Warrant Shares in the following name and to the following account:

 

	Issue to:	 
	 	 
	 	 
	 	 
	 	 

 

	Facsimile Number and Electronic Mail:	 

 

	Authorization:	 

 

	By:	 

 

	Title:	 

 

	Dated:	 

 

	Broker Name:	 
	 	 
	Broker DTC #:	 
	 	 
	Broker Telephone #:	 
	 	 
	Account Number:	 

	  (if electronic book entry transfer)	 

 

	Transaction Code Number:	 

	  (if electronic book entry transfer)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]